Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

CTNM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $3.82M rose 48.8% year over year, ahead of the +31.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 54.0% from the prior quarter. Over 3 fiscal years it compounded at +73.3% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +48.8% holds above the trailing-twelve-month pace of +31.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.82M+54.0% QoQ
Last fiscal yearDec 2025
$10.04M+47.5% YoY
LTMMar 2026
$11.29M+31.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.8%——
1 year+47.5%——
3-year CAGR+73.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.04M USD
Year-over-year change
+47.5%
4-year CAGR
+54.8%

Stock-Based Compensation vs competitors

How CTNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.2% is the 2nd highest of 7, against a peer median of -32.8%.
  • Over three fiscal years its annual growth of +73.3% compares with a peer median of +66.3%.
CTNM Competitors
Stock-Based Compensation for CTNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$27.96M USD-33.3%+53.3%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$21.78M USD+70.4%+213.9%108.9%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$11.29M USD+31.2%+73.3%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$7.02M USD-5.4%+66.3%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
GHRSGH Research PLCLTM Mar 2026$1.88M USD-32.3%——
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$1.37M USD———
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$125K USD-78.0%——
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding CTNM) —-32.8%+66.3%91.9%

Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29M)(24.25M)22.72M(42.26M)(59.98M)
Depreciation & Amortization325K329K195K258K323K
Deferred Income Tax00000
Stock-Based Compensation1.75M1.93M2.22M6.8M10.04M
Change in Working Capital108K(1.27M)(1.02M)5.33M(6.04M)
Accounts Receivables00000
Inventory00000
Accounts Payables(110K)(230K)01.14M(869K)
Other Working Capital218K(1.04M)(1.02M)4.19M(5.17M)
Other Non-Cash Items553K3.14M(4.76M)(2.98M)344K
Operating Cash Flow(26.27M)(20.12M)19.35M(32.85M)(55.31M)
Capital Expenditures(168K)(118K)(414K)(514K)(231K)
Acquisitions (Net)00020K0
Purchases of Investments(66.78M)(64.7M)(141.87M)(226.41M)(162.5M)
Sales of Investments1.98M87.12M76.71M157.16M159.02M
Other Investing Activities00000
Investing Cash Flow(64.97M)22.3M(65.57M)(69.74M)(3.71M)
Debt Repayment0(1.25M)(3.75M)00
Common Stock Issued000108.21M112.69M
Common Stock Repurchased0(4K)(28K)00
Dividends Paid00000
Other Financing Activities113K15K(184K)790K0
Financing Cash Flow79.84M(1.24M)56.18M109M112.69M
Effect of Forex Changes00000
Net Change in Cash(11.4M)939K9.96M6.42M53.66M
Free Cash Flow(26.43M)(20.24M)18.94M(33.36M)(55.54M)

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Intrinsic Alpha fair value

Locked

Current Price

$9.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.